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The heart is a major target organ for thyroid hormone action. Severe overt hypothyroidism can result in diastolic
hypertension, lowered cardiac output, impaired left ventricular contractility and diastolic relaxation, pericardial
effusion and bradycardia. However, the function of the atrial pacemaker is usually normal and the degree by which
the heart rate slows down is often modest. Here we report the case of a 20 year old male Caucasian with severe
overt hypothyroidism. He presented with syncopation due to second degree atrioventricular block type Mobitz 2
and heart failure with reduced ejection fraction (38 %). Laboratory testing revealed a severe overt hypothyroidism
with markedly elevated TSH (>100 mIU/L) and reduced fT3 and fT4 levels. The condition was caused by hypothyroid
Graves’ disease (Graves’ disease with Hashimoto component). Although magnetic resonance imaging of the heart
demonstrated decreased cardiac contractility and pericardial effusion, suggesting peri-myocarditis, plasma levels for
BNP and troponin I were low. A possible infectious cause was unlikely, since testing for cardiotropic viruses was
negative. The patient was treated with intravenous levothyroxine and after peripheral euthyroidism had been
achieved, left ventricular ejection fraction returned to normal and pericardial effusion dissolved. Additionally,
bradycardiac episodes abated, although intermittent second degree AV block was still occasionally present during the
night. In conclusion, overt hypothyroidism may be associated by cardiac myxedema affecting both electrophysiology
and contractility, observations that underscore the necessity of thyroid testing in different phenotypes of heart failure.
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From a clinical perspective the phenotype of hypothyroidism
is modulated by patient’s age [1], the rate of its onset,
and potential comorbidities.
Hypothyroidism is a known risk factor for cardiovascular
disease [2]. Atherosclerosis may result from dyslipidemia
[3] and diastolic hypertension [4], both conditions that
may be a consequence of thyroid hormone deficiency.
Myocardial dysfunction, both systolic and diastolic, is
also associated with hypothyroidism; congestive heart
failure may ensue, particularly in individuals with severe
thyroid hormone deficiency [5]. Pericardial effusions,
though usually small and of little significance, have been
identified in up to 50 % of patients with thyroid gland* Correspondence: apostolos.chatzitomaris@rub.de
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unless otherwise stated.failure [6–9]. Pericardial tamponade is rare but has been
reported [10–12]. Hypothyroidism classically has been
associated with bradycardia, but the degree, by which
the heart rate slows down, is often modest [13, 14]. The
function of the atrial pacemaker is normal and atrial
ectopy is rare, however premature ventricular beats and
occasionally ventricular tachycardia can occur [15].
Hypothyroidism may even be accompanied by the syn-
drome of torsade de pointes with a long QT interval
and ventricular tachycardia, which may resolve with
levothyroxine treatment [16]. Disturbances in atrioven-
tricular conduction have been described in myxedema,
but seem to be rare. The co-existence of impaired left
ventricular contractility, diastolic hypertension, increased
systemic vascular resistance, peripheral edema and de-
creased exercise tolerance suggests that hypothyroidism
may result in heart failure. However, hypothyroidism as a
sole cause of heart failure has been rarely reported [17–20].
Hypothyroid patients are able to increase their cardiacentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sponse to exercise, unlike patients with heart failure
[17, 18].
Graves’ disease is a B-cell mediated autoimmune disease
induced by the expression of autoantibodies to the
thyrotropin (TSH) receptor (TRAbs) as the major patho-
genic feature [19–21]. There are two general types of
TRAbs, which can each promote a type of autoimmune
thyroiditis (AITD): TSIs (also referred to as sTRAbs) that
mimic TSH stimulating the thyroid, which results in auto-
immune hyperthyroidism, or classical Graves’ disease; and
thyroid-blocking antibodies (TBAbs or iTRAbs), which
block he binding of TSH to its receptor and can result in
B cell-mediated autoimmune hypothyroidism [22–26].
Another type of hypothyroid Graves’ disease may ensue
from overlap with T cell-mediated thyroiditis (Graves’ dis-
ease with Hashimoto component), where hypothyroidism
ensues from destruction of thyroid tissue by cytotoxic T
cells. Although overlap syndromes are common in cases
of Graves’ disease they rarely lead to hypothyroidism com-
pared with classical Hashimoto’s or Ord’s disease.
Patient
A 20-year-old Caucasian male was admitted to the emer-
gency department of an external secondary care hospital
after he collapsed with syncopation while he watched a
football match in the stadium. He had lost consciousness
for less than a minute. Two years before he was diagnosed
to have hypothyroidism, and the prescribed medication
consisted of low dose levothyroxine and, for unknown rea-
sons, low dose of carbimazole, potentially because of high
TRAb titers. He was, however, taking his medication
irregularly. Upon hospital admission he complained of
increasing fatigue over the last two months. Dyspnea,
chest pain, weight gain and stool irregularity were denied
as well as symptoms and signs of previous viral infection
in the last months. At arrival, the patient was awake and
amenable, without showing any signs of alcohol consump-
tion. His body temperature was 35.8 °C, heart rate was
52 bpm and the blood pressure was 80/40 mmHg. The
physical examination was otherwise unremarkable. His
initial electrocardiography (ECG) showed sinus brady-
cardia without atrioventricular block and ST-segment
abnormalities. Echocardiography in the emergency de-
partment demonstrated impaired cardiac contractility
with ejection fraction (LVEF) of 38 % and a pericardial
effusion with maximal thickness of 15 mm without
hemodynamic relevance. All valves were well visualized
and appeared to be normal. Initial laboratory findings re-
vealed a TSH level of over 100 mIU/L, therefore the patient
was moved to our hospital in face of imminent myxedema
coma. We confirmed hypothyroidism with reduced levels
of plasma free thyroxine (fT4, < 3.9 pmol/L, see Table 1 for
reference ranges) and plasma free triiodothyronine (fT3, 2.4pmol/L) associated with massive rise in plasma thyrotropin
(TSH, 108 mIU/L). Creatin kinase (CK) was 437 U/L
(normal < 172) and CK-MB was 34 U/l (normal < 24).
However, troponin I and BNP concentrations were low.
Serum electrolytes, complete blood count, and basal
levels of cortisol and ACTH were normal. The patient
was transferred to the ICU, where treatment with intra-
venous infusion of levothyroxine (500 μg over the first
24 h) was commenced. ECG monitoring revealed an
intermittent atrioventricular block type Mobitz 2
(Fig. 1). In order to evaluate the pericardial effusion and
the impaired left ventricular ejection fraction, magnetic
resonance imaging was performed, which confirmed the
echocardiographic findings. A potential peri-myocarditis
was susptected because of the increased signal intensity in
the epicardial layer, suggesting local edema, in the T2-
weighted and late gadolinium enhancement images
(Fig. 2 and Additional file 1). Therefore, to rule out a
peri-myocarditis, serologic studies, including parvovirus-
B19, streptococcus, influenza-virus, mycoplasma, adeno-
virus, enterovirus, herpes virus type 6 and cytomegalovirus
were performed, which did not support the diagnosis.
Titres of three subtypes of anti-thyroid antibodies
were elevated, suggesting hypothyroid Graves’ disease
with Hashimoto component (TgAb > 2000 U/mL,
TPO-Ab > 3000 U/mL, TRAb 5,9 U/mL). After 3 days
the intravenous levothyroxine therapy was terminated
and oral substitution continued with a daily dose of
150 μg for 7 days, followed by 125 μg daily. After
7 days an echocardiography revealed normal LVEF and
the pericardial effusion had vanished. When peripheral
euthyroidism was achieved after 9 days, 24-h Holter ECG
monitoring demonstrated regression of the bradycardiac
episodes, however an intermittent atrioventricular block
Mobitz type 2 during the night remained. A pacemaker
was not considered because of a rise in the cardiac
frequency during training. In a follow-up MRI investigation
after 3 weeks, the initially increased signal intensity in the
epicardial layer in T2-weighted and late gadolinium en-
hancement images had been dissolved (Fig. 3 and Add-
itional file 2). Cardiac output had improved to 6.0 L/min
from formerly 3.2 L/min (Table 1).
Discussion
Pericardial effusion and impaired cardiac contractility
are common signs in hypothyroidism, and several cases
of cardiac tamponade due to hypothyroidism have been
described in the literature [6–12, 27–29]. Both abnor-
malities have been described to be reversible after
achievement of a euthyroid state. In our patient both
cardiac contractility and the pericardial effusion normalized
or dissolved after 9 days of treatment after euthyroidism
was reached. Disturbances in the conduction system of
the heart are infrequent in hypothyroidism [30, 31]
Table 1 Progression of thyroid hormone levels, ejection fraction and cardiac biomarkers after substitution therapy with
levothyroxine had been initiated. Reference ranges are reported with units of measurement
Days after
admission
0 0 1 2 5 9 28 83 120
(external)
Concentrations of thyroid hormones
TSH >100 108.34 >100 >100 >100 78.65 30.31 13.86 7.61
(0.35–3.5 mIU/L)
Free T3 2.4 2.7 2.7 3.1 4.5 4.2 4.2 4.4
(3.5–6.3 pmol/L)
Free T4 <3.9 <3.9 <3.9 6.44 9.0 12.87 12.87 16.73
(8–18 pmol/L)
Echocardiography and MRT
EF 25 38 60 55 58
(55–70 %)
Cardiac output 3.2 6.0
(2.8–8.8 L/min)
Concentrations of cardiac biomarkers






Fig. 1 ECG monitoring in overt hypothyroid state Fig. 2 Cardiac MRT before initiation of treatment
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Fig. 3 Cardiac MRT in peripheral euthyroid state
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vanced atrioventricular block in young individuals [32].
Affected patients with second and/or third degree AV
block in the setting of thyroid dysfunction almost al-
ways have to be provided with a permanent pacemaker
even after thyroid status has been normalized [13, 14,
33–36]. The reason for this is unclear. However, on a
molecular level the clinical phenomena found in
hypothyroid-associated cardiac disease may be ex-
plained by pleiotropic effects of thyroid hormones on
both gene expression and metabolism of myocardial
cells. Genomic mechanisms involve T3 binding to
TRs, which regulate transcription of specific cardiac
genes. Positively regulated are alpha-myosin heavy chain,
sarcoplasmic reticulum Ca2+-ATPase, Na+/K+-ATPase,
beta1-adrenergic receptor, atrial natriuretic hormone and
voltage-gated potassium channels (Kv1.5, Kv4.2, Kv4.3).
Negatively regulated are beta-myosin heavy chain,
phospholamban, adenylyl cyclase catalytic subunits,
thyroid hormone receptor alpha1 and Na+/Ca2+ ex-
changer. Non-genomic mechanisms include direct
modulation of membrane ion channels. Additional
extracardiac effects of thyroid hormones on cardiovas-
cular hemodynamics include stimulation of tissue
thermogenesis, increase of cardiac output and pulmonary
pressure, and decrease of both systemic vascular resist-
ance and diastolic blood pressure with consecutively re-
duced afterload. Isovolumic relaxation time, as a measureof diastolic function, is increased in subclinical and
even more in overt hypothyroidism. Cardiovascular
risks associated with hypothyroidism include impaired
cardiac contractility and diastolic function, increased
systemic vascular resistance, possibly caused by de-
creased endothelial-derived relaxation factor, and ele-
vated levels of serum cholesterol, C-reactive protein
and homocysteine [37]. Abnormal cardiac bioenerget-
ics in hypothyroidism is improved by substitution with
levothyroxine [38].
In addition, regulation of beta-receptor density by
thyroid hormones, as described on both genomic and
non-genomic levels, could play a key role in this scenario
[39, 40]. Fast non-genomic effects may be mediated by
microtubule assembly [41].
Moreover, thyroid hormones have profound effects
on myocardial calcium and potassium channels on
both RNA and protein level. Hypothyroidism-induced
remodelling of K+ channels expression is assumed to
be responsible for the blunted response of peak transient
outward current (Ito) and sustained current (Isus, a mix of
IK, slow and Iss) to changes in membrane potential [42].
Undiagnosed and/or untreated hypothyroidism may
pose a threat of sudden cardiac death, which may be
mirrored by myocardial ventricular late potentials in
overt hypothyroidism [43].
Conclusion
Hypothyroidism is a differential diagnosis of suspected
peri-myocarditis. This case underscores the clinical rele-
vance of thyrocardiac interaction. Evaluation of thyroid
homeostasis should be performed early in the work-up
of heart failure and every kind of arrhythmia. Even
though electrophysiological scars may outlast myx-
edema, it may be life-saving to commence substitution
therapy with thyroid hormones timely.
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